Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.65 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.65 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.65 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.65 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.65 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | MLYCD | O95822 | 1/20 | 0.58 |
| ▸ | PLAU | P00749 | 3/20 | 0.56 |
| ▸ | HPN | P05981 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093916 | 0.85 | HSD17B10 (0.66) | ALDH1A1HPGDHTTRAB9ASMN1; SMN2 | |
| SCHEMBL21336212 | 0.83 | HSD17B10 (0.60) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL18880072 | 0.82 | ALDH1A1 (0.73) | ALDH1A1HPGDHTTRAB9ASMN1; SMN2 | |
| SCHEMBL12545727 | 0.81 | ALDH1A1 (0.58) | ALDH1A1HPGDHTTRAB9ASMN1; SMN2 | |
| SCHEMBL4100751 | 0.80 | HPN (0.61) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL7903320 | 0.79 | F2 (0.71) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL22199591 | 0.79 | ALDH1A1 (0.66) | ALDH1A1HPGDHTTRAB9ASMN1; SMN2 | |
| SCHEMBL7278525 | 0.79 | ALDH1A1 (0.71) | ALDH1A1HPGDHTTRAB9ASMN1; SMN2 | |
| SCHEMBL18896262 | 0.79 | ALDH1A1 (0.66) | ALDH1A1HPGDHTTRAB9ASMN1; SMN2 | |
| SCHEMBL14254805 | 0.79 | ALDH1A1 (0.66) | ALDH1A1HPGDHTTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160338957-A1 | IMINO COMPOUNDS FOR AMPHOTERIC LIPOSOMES AND USES THEREOF | BIONTECH PROTEIN THERAPEUTICS GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8642582-B2 | Morpholinone compounds as factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642582-B2 | Morpholinone compounds as factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
| EP-2075250-A2 | Thrombin receptor antagonists | SCHERING CORPORATION (US) | 2009-07-01 | — | — | EP | disclosed |
| US-7488752-B2 | nor-seco himbacine derivatives; thrombosis, anticoagulants, anticancer agents; antiinflammatory agents; anticholesterol agents; cardiovascular disorders; antiarrhythmia agents; antiischemic agents; strokes; antiarthritic agents | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160338957-A1 | IMINO COMPOUNDS FOR AMPHOTERIC LIPOSOMES AND USES THEREOF | IPO8, IPO7, PHOSPHO1 | F2 2554/4885PRSS1 4359/4885PRSS2 3626/4885 |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | F2 14/4885PRSS1 405/4885PRSS2 1421/4885 |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | F2 14/4885PRSS1 405/4885PRSS2 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.